CPA Asset Management LLC acquired a new position in Johnson & Johnson (NYSE:JNJ – Get Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,073 shares of the company’s stock, valued at approximately $1,956,000. Johnson & Johnson makes up about 1.5% of CPA Asset Management LLC’s investment portfolio, making the stock its 17th biggest holding.
A number of other hedge funds also recently bought and sold shares of JNJ. Zevin Asset Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $207,000. Commonwealth Equity Services LLC lifted its holdings in shares of Johnson & Johnson by 1.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 1,769,186 shares of the company’s stock valued at $312,526,000 after purchasing an additional 26,167 shares during the last quarter. Benjamin Edwards Inc. lifted its holdings in shares of Johnson & Johnson by 13.0% during the 4th quarter. Benjamin Edwards Inc. now owns 13,883 shares of the company’s stock valued at $2,452,000 after purchasing an additional 1,596 shares during the last quarter. Journey Advisory Group LLC lifted its holdings in shares of Johnson & Johnson by 12.9% during the 4th quarter. Journey Advisory Group LLC now owns 57,969 shares of the company’s stock valued at $10,240,000 after purchasing an additional 6,608 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Johnson & Johnson by 2.2% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 101,886 shares of the company’s stock valued at $17,998,000 after purchasing an additional 2,159 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Analysts Set New Price Targets
Several analysts have recently commented on JNJ shares. Atlantic Securities decreased their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Guggenheim initiated coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. SVB Leerink cut their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Finally, Credit Suisse Group increased their price target on Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $173.00.
Insiders Place Their Bets
Johnson & Johnson Trading Down 0.8 %
JNJ stock opened at $161.05 on Wednesday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $183.35. The stock has a market cap of $418.53 billion, a price-to-earnings ratio of 33.69, a PEG ratio of 2.78 and a beta of 0.53. The business’s 50-day moving average is $158.62 and its 200 day moving average is $166.91.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. During the same period last year, the company posted $2.67 EPS. The business’s revenue was up 5.6% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 2.96%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 94.56%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
